81 results
8-K
EX-99.1
ENVB
Enveric Biosciences Inc
26 Mar 24
Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023
8:00am
of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent
8-K
EX-99.1
ENVB
Enveric Biosciences Inc
19 Mar 24
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive
7:00am
; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related
8-K
EX-99.1
ENVB
Enveric Biosciences Inc
29 Feb 24
Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds
7:00am
of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal
8-K
EX-99.1
ENVB
Enveric Biosciences Inc
21 Feb 24
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders
8:05am
; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related
8-K
nrtt55uvh
8 Jan 24
Cost Associated with Exit or Disposal Activities
4:42pm
8-K
EX-99.1
moqahe2g
3 Jan 24
Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series
8:05am
8-K
EX-99.1
9c7 119pcubvhuanoh
29 Dec 23
Entry into a Material Definitive Agreement
4:43pm
8-K
EX-99.1
vrkcu zcwn2ap
28 Dec 23
Enveric to initiate preclinical development of EB-003 in 2024 in preparation for IND submission
8:05am
8-K
EX-99.1
g1vk8j9no0y 5y21f9
27 Dec 23
Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373
8:05am
8-K
EX-99.1
h5li1
5 Dec 23
Three novel neuroplastic compounds identified with plans to advance one into expedited preclinical development in 2024
8:05am
8-K
EX-99.1
zk7y9mx4u3wdw
29 Nov 23
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives
8:18am
8-K
EX-99.1
7pa agtpn9tf
13 Nov 23
Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results
4:10pm
8-K
EX-99.1
stas2eq
31 Oct 23
Regulation FD Disclosure
8:05am
8-K
EX-99.1
e1p99nu25dkum8bzoj9
20 Oct 23
Enveric Biosciences to Present at the Centurion One 5th Global Summit
8:05am
8-K
EX-99.1
x7cay5fy2c esvjcl
18 Oct 23
Key preclinical milestone designed to establish safety profile and maximum tolerated dose for anticipated clinical trial of EB-373
8:05am
8-K
EX-99.1
wy8mo7a4o cf
11 Oct 23
Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit
8:05am
8-K
EX-99.1
5o3f48
3 Oct 23
Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates
8:05am
8-K
EX-99.1
9d9rjb
27 Sep 23
Regulation FD Disclosure
8:05am
8-K
EX-99.1
er7w6hihga5y 6ancm10
20 Sep 23
Regulation FD Disclosure
8:05am